Sugammadex for Postoperative Complications

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Postoperative Complications+2 MoreSugammadex - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will compare the effects of two drugs given to reverse paralysis after surgery - one has no effect on bowel function, while the other does.

Eligible Conditions
  • Postoperative Complications
  • Neuromuscular Blockade
  • Irritable Bowel Syndrome (IBS)

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 30 minutes after the administration of reversal drug.

0, 15, 30, 45, 60, 90, 120, and 150 minutes after neuromuscular reversal
Gastric emptying
1 day
PACU phase 1 recovery time
30 minutes after the administration of reversal drug.
Time in minutes to reach train of four (TOF) ratio ≥ 0.9 after the administration of reversal drug.
60 days after surgery
Gastrointestinal complications
Week 1
Bowel movement
Week 1
Hospital length of stay

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Neostigmine
1 of 2
Sugammadex
1 of 2

Active Control

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: Sugammadex · No Placebo Group · Phase 4

Sugammadex
Drug
Experimental Group · 1 Intervention: Sugammadex · Intervention Types: Drug
Neostigmine
Drug
ActiveComparator Group · 1 Intervention: Neostigmine · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sugammadex
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 minutes after the administration of reversal drug.

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
3,674 Previous Clinical Trials
4,959,280 Total Patients Enrolled
5 Trials studying Postoperative Complications
893 Patients Enrolled for Postoperative Complications
Oregon Health and Science UniversityLead Sponsor
893 Previous Clinical Trials
6,829,254 Total Patients Enrolled
2 Trials studying Postoperative Complications
202 Patients Enrolled for Postoperative Complications
Brandon M Togioka, MDPrincipal Investigator - Oregon Health and Science University
Oregon Health and Science University
6 Previous Clinical Trials
682 Total Patients Enrolled
1 Trials studying Postoperative Complications
200 Patients Enrolled for Postoperative Complications

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: